Wechselwirkungen von Levomilnacipran

Intervention: Avoid concomitant use of FETZIMA and alcohol [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Amfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (Fachinformation zu Amfetamin und Dexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs), including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Belladonna und Opium, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Arzneimittelwechselwirkungen)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Butorphanol, Vorsichtsmaßnahmen)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (Fachinformation zu Carbamazepin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Codein, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (Fachinformation zu Dexamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (Fachinformation zu Dronedaron, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (Fachinformation zu Edoxaban, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (Fachinformation zu Flumazenil, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Ibuprofen, Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Paracetamol, Vorsichtsmaßnahmen)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Levorphanol, Vorsichtsmaßnahmen)

Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ) and Warnings and Precautions ( 5.2 )] . (Fachinformation zu Levomilnacipran, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Lisdexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (Fachinformation zu Lorazepam, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ) and Warnings and Precautions ( 5.2 )] . (Fachinformation zu Levomilnacipran, Gegenanzeigen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Morphin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Paracetamol und Codein, Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Pentazocin und Naloxon, Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (Fachinformation zu Promethazin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Promethazin und Codein, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Remifentanil, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation. with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. (Fachinformation zu Levomilnacipran, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin-norepinephrine reuptake inhibitors (SNRIs), including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Arformoterol, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Articain und Adrenalin, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Budesonid und Formoterol, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (Fachinformation zu Bupivacain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

…hydrochloride extended-release tablets (XL), concurrent administration of bupropion hydrochloride extended-release tablets (XL) and agents that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids) should be undertaken only with extreme caution [see Warnings and Precautions (5.3)] . (Fachinformation zu Bupropion, Arzneimittelwechselwirkungen)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (Fachinformation zu Carbidopa, Levodopa und Entacapon, Arzneimittelwechselwirkungen)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (Fachinformation zu Carisoprodol, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Cinacalcet, Arzneimittelwechselwirkungen)

…syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (Fachinformation zu Ciprofloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (Fachinformation zu Clonazepam, Arzneimittelwechselwirkungen)

Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (Fachinformation zu Clonidin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (Fachinformation zu Daridorexant, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (Fachinformation zu Darifenacin, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (Fachinformation zu Diazepam, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (Fachinformation zu Dikaliumclorazepat, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (Fachinformation zu Dronabinol, Warnhinweise und Vorsichtsmaßnahmen)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (Fachinformation zu Droperidol, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Fachinformation zu Eszopiclon, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Formoterol, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (Fachinformation zu Foscarnet, Arzneimittelwechselwirkungen)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (Fachinformation zu Fosfomycin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Gefitinib, Arzneimittelwechselwirkungen)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (Fachinformation zu Glycopyrroniumbromid, Arzneimittelwechselwirkungen)

Plasma concentrations of CYP2D6 substrates (e,g. tricyclic antidepressants such as desipramine or imipramine) may increase when they are co-administered with haloperidol. (Fachinformation zu Haloperidol, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (Fachinformation zu Ipratropiumbromid und Salbutamol, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (Fachinformation zu Isoprenalin, Arzneimittelwechselwirkungen)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Examples: Ketoconazole, itraconazole, clarithromycin Alcohol Clinical Impact: Concomitant use of FETZIMA and alcohol may result in accelerated release of levomilnacipran. (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (Fachinformation zu Lemborexant, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (Fachinformation zu Levosalbutamol, Arzneimittelwechselwirkungen)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Lidocain, Arzneimittelwechselwirkungen)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (Fachinformation zu Lidocain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (Fachinformation zu Lumateperon, Warnhinweise und Vorsichtsmaßnahmen)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (Fachinformation zu Lurasidon, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (Fachinformation zu Mefloquin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (Fachinformation zu Mepivacain, Warnhinweise)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (Fachinformation zu Methylscopolamin, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (Fachinformation zu Moxifloxacin, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (Fachinformation zu Nalbuphin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (Fachinformation zu Natriumoxybat, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Inform patients about the increased risk of bleeding associated with the concomitant use of FETZIMA and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions ( 7.1 )] . (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (Fachinformation zu Phenylephrin, Arzneimittelwechselwirkungen)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (Fachinformation zu Physostigmin, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. (Fachinformation zu Pimozid, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Prilocain und Adrenalin, Arzneimittelwechselwirkungen)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (Fachinformation zu Quetiapin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salbutamol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (Fachinformation zu Scopolamin, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Arzneimittelwechselwirkungen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (Fachinformation zu Temazepam, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Fachinformation zu Terbutalin, Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

The CNS depressant effects of Zanaflex with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . (Fachinformation zu Tizanidin, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (Fachinformation zu Toremifen, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Umeclidiniumbromid und Vilanterol, Arzneimittelwechselwirkungen)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (Fachinformation zu Vasopressin, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Examples: NSAIDs, aspirin, and warfarin Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of FETZIMA with strong CYP3A4 inhibitors increases levomilnacipran exposure [see Pharmacokinetics ( 12.3 )] . (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (Fachinformation zu Zaleplon, Warnhinweise)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (Fachinformation zu Zolpidem, Warnhinweise und Vorsichtsmaßnahmen)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (Fachinformation zu Benzatropin, Warnhinweise)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (Fachinformation zu Brexpiprazol, Warnhinweise und Vorsichtsmaßnahmen)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (Fachinformation zu Carbidopa, Arzneimittelwechselwirkungen)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (Fachinformation zu Cariprazin, Warnhinweise und Vorsichtsmaßnahmen)

Cytochrome P450 IID6 is an enzyme critical to the metabolism of many drugs, notably including mexiletine , some phenothiazines , and most polycyclic antidepressants . (Fachinformation zu Chinidin, Arzneimittelwechselwirkungen)

Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide). (Fachinformation zu Clozapin, Arzneimittelwechselwirkungen)

Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones. (Fachinformation zu Dofetilid, Warnhinweise)

Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (Fachinformation zu Hydroxyzin, Vorsichtsmaßnahmen)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (Fachinformation zu Lovastatin, Warnhinweise)

Activation of mania/hypomania has also been reported in a small proportion of patients with mood disorders who were treated with other antidepressants. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (Fachinformation zu Levomilnacipran, Arzneimittelwechselwirkungen)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Fachinformation zu Perphenazin, Arzneimittelwechselwirkungen)

Such drugs may include many antiarrhythmics, some phenothiazines, tricyclic antidepressants, and oral macrolides. (Fachinformation zu Propafenon, Warnhinweise und Vorsichtsmaßnahmen)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (Fachinformation zu Propranolol, Arzneimittelwechselwirkungen)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (Fachinformation zu Tiagabin, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (Fachinformation zu Trihexyphenidyl, Arzneimittelwechselwirkungen)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (Fachinformation zu Valproat-Seminatrium (Divalproex), Arzneimittelwechselwirkungen)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (Fachinformation zu Valproinsäure, Arzneimittelwechselwirkungen)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (Fachinformation zu Entacapon, Vorsichtsmaßnahmen)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Fachinformation zu Ropinirol, Arzneimittelwechselwirkungen)